Dogs join fight against bone cancer

May 15, 2014 by Dennis Thompson, Healthday Reporter
Dogs join fight against bone cancer
FDA-approved drugs to be tested on canines with bone cancer that also affects humans

(HealthDay)—Man's best friend will be part of an effort to find better treatments for a type of bone cancer in children and young adults, researchers report.

Dogs who are suffering from will be treated with drugs that are already approved by the U.S. Food and Drug Administration for other uses, to see how well these medications battle the bone cancer, said Dr. Joy Fulbright, a pediatric oncologist with Children's Mercy Hospital in Kansas City, Mo.

"This is one of the cancers that is the same type of cancer in both dogs and humans, and dogs tend to be able to process drugs similarly to how humans do," Fulbright said. "Ideally, we'd like to find an agent that's not as toxic as the chemotherapy we currently use."

Doctors are hoping that they'll find drugs that are effective against osteosarcoma in both dogs and humans. And, because these medications are already FDA-approved, they should be able to put them to use very quickly.

"It usually takes up to 15 years to get a drug from bench side to patient," Fulbright said. "We're hoping to decrease that time if we can find a drug that's already FDA-approved."

Finding new treatments for osteosarcoma has been a challenge because it's an uncommon cancer in humans. Only about 800 people are diagnosed with the disease each year, about 400 of those are in children and teens, according to the American Cancer Society.

The five-year survival rates for people diagnosed with osteosarcoma before it has spread can be as high as 80 percent. If the cancer has spread, five-year survival rates drop to between 15 percent and 40 percent, according to the cancer society.

"We haven't improved the survival rate in the last 20 years," Fulbright said.

However, osteosarcoma is far more common in dogs than it is in people. About 10,000 cases are diagnosed each year, according to the study authors.

Currently, the researchers are pre-testing drugs in the laboratory using osteosarcoma cells taken from both humans and canines.

The most promising candidates from this phase will then be tested in dogs that have been diagnosed with bone cancer, to see which work best with the least side effects. Vets at the Colorado State University College of Veterinary Medicine will identify canine candidates for the study and treat them with the drugs selected by researchers. No dogs will be given cancer for this study; the dogs must have naturally occurring osteosarcoma.

After identifying drugs that work for dogs, doctors hope to move on to human trials using the same medications.

Canines are commonly used in medical research, said Nicole Duffee, director of education and scientific affairs for the American Association for Laboratory Animal Science.

Their use in this study makes sense because osteosarcoma "is a naturally occurring condition in dogs, especially in large dogs," Duffee said.

Duffee noted that while the study is focused on a human treatment for osteosarcoma, it could also lead to improved treatments for .

The study is being funded with a $500,000 grant from the Midwest Cancer Alliance.

Explore further: Researchers say gold-based drug shows promise for fighting bone cancer in people and pets

More information: Visit the American Cancer Society for more on osteosarcoma.

Related Stories

Researchers say gold-based drug shows promise for fighting bone cancer in people and pets

March 26, 2014
(Medical Xpress)—A gold-based drug currently used in human and veterinary medicine to manage certain immune diseases may prove useful in combating osteosarcoma, a devastating bone cancer that affects both dogs and people, ...

Water fluoride levels do not increase risk of bone cancer

January 23, 2014
(Medical Xpress)—Fluoride levels in drinking water do not lead to a greater risk of primary bone cancer, a new study has found.

Recommended for you

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

How CD44s gives brain cancer a survival advantage

July 19, 2017
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease. In the case of glioblastoma multiforme, the deadliest ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.